A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors

Solid Tumors Clinical Trial

Official title:

A Randomized, Open-label, Phase I, Crossover Study to Assess the Effect of Food on the Bioavailability of AXL1717, in Patients With Advanced Malignant Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01725555
• Other study ID #: AXL010
• Status: Completed
• Phase: Phase 1
• First received: October 26, 2012
• Last updated: April 4, 2014
• Start date: October 2012
• Est. completion date: December 2013

Study information

• Verified date: April 2014
• Source: Axelar AB
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products AgencySweden: Regional Ethical Review BoardSweden: Swedish Data Inspection Board
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, open-label, Phase I, crossover study to assess the effect of food on the bioavailability of AXL1717 including patients with advanced malignant tumors

Description:

This is a randomized, crossover, open label, phase I study to assess the effect of food on the bioavailability of AXL1717 in advanced cancer patients.

A single, oral dose of AXL1717 is to be administered to patients on each of two occasions that are 7-day apart, in random order: after an overnight fast (fasted treatment) and with a high-fat or moderate-fat breakfast (fed treatment).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be informed of the nature of the study and have provided written informed consent

2. At least 18 years of age

3. Histologically confirmed diagnosis of advanced solid or hematological malignancy not amenable to standard treatment.

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 after optimization of analgesics

5. Life expectancy = 3 months

6. Hematology values: blood leukocyte count = 3.0 x 109/L, blood absolute neutrophil count = 1.5 x 109/L, blood platelet count = 100 x109/L, hemoglobin = 100 g/L (transfusions are allowed)

7. Clinical chemistry values: plasma total bilirubin level = 1.5 times the upper limit of the "normal" range (ULN; i.e. reference), plasma AST or ALT = 1.5 x ULN (=5 times if liver metastases have been documented) and plasma creatinine = 1.5 x ULN

8. 12-lead ECG with normal tracings; or changes that are not clinically significant and do not require medical intervention

Exclusion Criteria:

1. Ongoing infection or other major recent or ongoing disease that, according to the Investigator, poses an unacceptable risk to the patient

2. Known primary or secondary central nervous system malignancy. (Patients with symptoms suggestive of possible CNS metastasis such as headache, dizziness or focal neurological deficits should undergo CT or MRI of the brain to rule out CNS metastasis. Patients who do not have CNS symptoms do not need a CT or MRI of the brain.)

3. Grade 3 or higher constipation within the past 28 days or grade 2 constipation within the past 14 days before randomization. (Patients with grade 2 constipation within the past 14 days could be re-screened if constipation decreases to = grade 1 with optimal management of constipation.)

4. Impairment of gastrointestinal (GI) function, GI cancer or GI disease that may significantly alter the absorption of AXL1717

5. Coexisting uncontrolled medical condition, including active cardiac disease (such as unstable angina, myocardial infarction within 6 months, or New York Heart Association Class III/IV congestive heart failure), or significant dementia

6. Hepatic impairment as indicated by abnormalities of transaminases and/or alkaline phosphatase (AST and/or ALT > 1.5 × upper limit of normal concomitant with alkaline phosphatase > 2.5 × upper limit of normal, =5 times if liver metastases have been documented)

7. Major surgical procedure within 4 weeks prior to randomization

8. Use of potent inhibitors of CYP2C9 (e.g. Fluconazole) from 3 weeks prior to first administration of investigational product

9. Women of child bearing potential (WOCBP) who do not consent to using acceptable methods of contraception (i.e. two of the following - oral contraception, barrier contraception, intrauterine device). For purposes of this study, WOCBP include any female who has experienced menarche, who has not undergone tubal ligation, and who is not postmenopausal. Post menopause is defined as: amenorrhea = 12 consecutive months without another cause.

10. Women who are breast-feeding or have a positive pregnancy test at screening

11. Current participation in any other investigational clinical trial or any administration of an investigational agent within 4 weeks of study drug administration or 10 half-lives of the investigational agent, whichever is longer. Patients with unresolved investigational treatment-related AEs may not participate.

12. Known or suspected hypersensitivity to AXL1717

13. Lack of suitability for participation in the trial, for any reason, as judged by the Investigator

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Hematological Malignancies
• Neoplasms
• Solid Tumors

Intervention

Drug:
• Fasted treatment: AXL1717

• Fed treatment: AXL1717

Locations

Country	Name	City	State
Sweden	KFUE	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Axelar AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Single dose AXL1717 serum pharmacokinetic profile under fasting versus fed condition in each patient		several samples within 24 hours	No
Secondary	Safety of AXL1717 through adverse event reporting		Up to 30 days after last dose of study drug	Yes